What is GLP-1, and what does it do?
GLP-1 stands for glucagon-like peptide-1. That is a mouthful, so think of it simply as a messenger. It is a hormone — a chemical messenger that travels in your blood — and your gut (your stomach and intestines) releases it right after you eat.
GLP-1 has a few jobs, all about handling the meal you just had. It nudges your body to release a little more insulin, the substance that helps move sugar out of your blood and into your cells. It quiets a second hormone called glucagon, whose job is the opposite — glucagon tells your liver to put more sugar into your blood. GLP-1 also slows down how fast your stomach empties, and it tells your brain that you are full, so you stop eating sooner.
There is one catch. Your own GLP-1 does not last long at all. Your body breaks it down within minutes. So that helpful "I am full, and my blood sugar is handled" signal fades fast, almost as soon as it arrives.
What is a 'GLP-1 receptor agonist'?
Let us take that name apart, because it sounds more complicated than it is. A "receptor" is like a lock on the surface of a cell. GLP-1 is the key that fits that lock. When the key turns the lock, the cell gets the message and acts on it.
An "agonist" is just a word for something that turns the lock the same way the real key does. So a GLP-1 receptor agonist is a medicine built to act like your natural GLP-1 — it turns the same lock and sends the same message.
The clever part is timing. Your own GLP-1 disappears in minutes. These medicines are built to last about a week instead. Because the message stays switched on far longer, the "I am full" and "blood sugar handled" effects keep working steadily, day after day, between doses. That is the whole point of the design.
How do these medicines actually cause weight loss and lower blood sugar?
Start with blood sugar. When you eat, sugar from food enters your blood. GLP-1 signaling nudges your body to release more insulin, which helps clear that sugar out of the blood. At the same time it quiets glucagon, the hormone that would otherwise push more sugar in. Less sugar going in, more help clearing it out — so blood sugar runs lower and steadier. This is why this kind of medicine was first used for type 2 diabetes, a condition where blood sugar runs too high.
Now the weight side, which comes down to eating less without a daily fight. Because the medicine slows your stomach, food stays with you longer, so you feel full sooner and stay full longer. And because it quiets hunger in the brain, you simply want less food and think about it less often.
Put those together and most people eat less over the day, almost automatically. Eating less, week after week, is what leads to weight loss. The medicine is not burning fat directly. It is turning hunger down so that eating less stops feeling like a constant battle.
One thing many people notice is that this feels different from white-knuckle dieting. With ordinary calorie-cutting, hunger usually fights back harder the more weight you lose, which is part of why diets are so hard to keep up. These medicines work further upstream — they turn down the hunger signal itself, rather than asking you to resist it. That is the practical difference people describe: less willpower spent, because there is simply less hunger to push against in the first place.
One, two, or three signals: how the drugs differ
Here is the part that confuses almost everyone. These medicines do not all copy the same number of gut signals. Some copy one, some copy two, and a newer one copies three. Picture light switches in a room: copying more signals is like flipping more switches at once.
Semaglutide copies one signal: GLP-1. It is one switch. In a large study, people on semaglutide lost about 14.9 percent of their body weight over 68 weeks. Semaglutide is approved by the FDA — that is the part of the US government that checks medicines are safe and that they work — and it is sold under brand names you may know, like Ozempic for type 2 diabetes and Wegovy for weight.
Tirzepatide copies two signals: GLP-1 plus a second gut messenger called GIP. That is two switches. In its own large study, people on the 15 milligram dose lost about 20.9 percent of their body weight over 72 weeks. Tirzepatide is also FDA-approved, and you may know it as Mounjaro or Zepbound.
Retatrutide copies three signals: GLP-1, GIP, and glucagon. That is three switches. Here is the important part to be clear about: retatrutide is still being tested in studies. It is investigational — not approved by the FDA, and not something you can buy. "Still being studied" and "approved for use" are very different things, and it matters to keep them apart.
It is tempting to read "more switches" as simply "better," but that is not how to think about it. More signals did line up with bigger average weight loss across these separate trials, and that is genuinely interesting. Yet these were different studies in different people, not a single head-to-head race, and the right medicine for any one person depends on far more than which number is largest — tolerability, other health conditions, and how that person actually responds all matter. The number of switches is a useful way to tell the drugs apart, not a ranking of which is best for you.
| Medicine | Signals copied | FDA status | Avg. weight change in main trial |
|---|---|---|---|
| Semaglutide | One: GLP-1 | FDA-approved | −14.9% over 68 weeks (STEP 1) |
| Tirzepatide | Two: GLP-1 + GIP | FDA-approved | −20.9% at 15 mg over 72 weeks (SURMOUNT-1) |
| Retatrutide | Three: GLP-1 + GIP + glucagon | Investigational — not approved | −24.2% at 12 mg over 48 weeks (Phase 2) |
What are the common side effects, and why?
The most common side effects with this whole family of medicines are stomach-related: feeling sick (nausea), diarrhea, throwing up, or being constipated. They are described as dose-dependent, which simply means they tend to show up more at higher doses.
Once you remember how the medicine works, this makes sense. It slows your stomach down on purpose. So food sits longer, and your gut has to adjust to the new pace. That adjustment is what your tummy is reacting to.
This is also why doctors usually start at a low dose and raise it slowly. Going up gradually gives your stomach time to get used to the change, and the side effects tend to ease as your body settles in. Even so, everyone is different, and side effects are a real thing to talk through with a doctor rather than push through alone.
How are these medicines actually taken?
Almost all of these medicines are given the same basic way: a small injection under the skin, usually once a week rather than every day. The once-a-week design is deliberate. Because each dose keeps working for about a week, there is no daily routine to remember — the steady "I am full" signal is built to carry across all the days between shots. The two big weight trials in this space tested exactly that once-weekly schedule.
There is also a near-universal rule about the dose: start low, go slow. Doctors begin people on a small amount and raise it gradually over weeks or months rather than starting at full strength. This is on purpose, and it ties straight back to how the drug works.
Because the medicine slows the stomach, jumping to a high dose too fast is what tends to make people feel sick. Starting low gives the gut time to adjust to the new, longer fullness signal. By the time the dose is higher, the stomach has usually settled and handles it far better. None of this is dosing advice — the actual schedule is set and adjusted by a prescribing clinician for each person, because the right dose depends on how someone responds and what else is going on with their health.
Do these medicines do anything beyond weight and blood sugar?
For a long time this family of medicines was thought of as "just" blood-sugar and weight drugs. More recent research suggests the story is bigger. In a large trial called SELECT, people who already had heart disease and were living with overweight or obesity — but did NOT have diabetes — were given either semaglutide or a dummy injection and followed for several years.
The people on semaglutide had about 20 percent fewer major heart problems — a combined count of heart-related death, non-fatal heart attack, and non-fatal stroke — than the people on the placebo. In plain terms, roughly one in five of those serious events was avoided. That mattered, because it suggested at least part of the benefit was not only about the number on the scale.
Two cautions keep this honest. First, that result came from a specific group: people who already had heart disease plus excess weight. It does not mean everyone on a GLP-1 medicine gets the same heart protection. Second, a benefit found in a trial is still a decision for a doctor, who weighs it against side effects and a person's full history. But it does help explain why interest in this drug family has grown well beyond weight loss alone.
What happens if you stop taking a GLP-1 medicine?
This is one of the most common and most important questions, and the research gives a fairly clear answer. These medicines work while you take them. They turn the "I am full" signal up. When you stop, that signal drifts back toward where it was before — and for many people, so does the appetite that drove the original weight gain.
A trial called STEP 4 showed this directly. Everyone first took semaglutide for 20 weeks and lost weight. Then half kept taking it and half quietly switched to a dummy injection. Over the next 48 weeks, the group that stayed on semaglutide lost about another 7.9 percent of their body weight, while the group that switched to placebo regained about 6.9 percent. Same people, same starting point — the difference was simply whether the medicine was still on board.
The takeaway is not that the medicine "failed." It is that obesity behaves like a long-term condition — more like high blood pressure than like a short illness you finish treating. For many people the weight tends to return when the treatment stops. That is exactly why how long to stay on a medicine, and how to come off it if you do, is a real plan to make with a doctor rather than something to guess at alone.
Keeping track of it all with PeptidePanel
If a doctor decides one of these medicines is right for a person and prescribes it, there is real day-to-day stuff to keep track of: when the next dose is due, how weight is trending, and the lab numbers a doctor watches over time. That is easy to lose track of in your head.
PeptidePanel is a simple tracking tool for exactly that. It records the plan a doctor set, charts the results, and reminds you when something is due. It does not sell, supply, or recommend any medicine, and nothing here is medical advice. The decision to start any GLP-1 medicine — and which one — belongs to you and a licensed clinician who knows your full history. PeptidePanel is just the notebook that keeps that plan organized.